Antidiotypic monoclonal antibodies for treatment of melanoma

Details Antidiotypic monoclonal antibodies for treatment of melanoma Antidiotypic monoclonal antibodies for treatment of melanoma

1995-10-27

1998-07-14

Hutzell, Paula K.

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Anti-idiotypic

4241381, 4241411, 4241551, 4241781, 435327, 435330, 5303872, 5303877, A61K 39395, C07K 1600, C12N 500

Patent

active

057800294

ABSTRACT:
The invention concerns murine antiidiotypic monoclonal antibodies which are the internal image of determinants recognized by a monoclonal antibody on high molecular weight-melanoma associated antigen (HMW-MAA), antibody derivatives, hybridoma cell lines secreting such antiidiotypic monoclonal antibodies, and processes for the preparation of such antiidiotypic monoclonal antibodies, of their derivatives and of the hybridoma cell lines. The murine antiidiotypic monoclonal antibodies are useful for the determination of antibodies directed against high molecular weight-melanoma associated antigen, for the modulation of the immune response to HMW-MAA and for the treatment of melanoma.

REFERENCES:
Jurincic et al. J. Urol. 139(4) 723-6, 1988.
Herr, Uremia Invest. 8:257-61 (1985).
Kusama et al. Cancer Res. 47:4312-17, 15 Aug. 1987.
Giacomini et al. J. Immunol. 135:696-702, 1985.

Affiliated with

Also associated with

Rating

Antidiotypic monoclonal antibodies for treatment of melanoma does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antidiotypic monoclonal antibodies for treatment of melanoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antidiotypic monoclonal antibodies for treatment of melanoma will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1879235